amprenavir

(redirected from 141W94)
Also found in: Medical.
Translations

amprenavir

n amprenavir m
References in periodicals archive ?
Cross-resistance": HIV isolates obtained from 5 patients during nelfinavir therapy showed a 5- to 93-fold decrease in nelfinavir susceptibility in vitro when compared to matched baseline isolates, but did not demonstrate a concordant decrease in susceptibility to indinavir, ritonavir, saquinavir or 141W94, in vitro.
Agenerase (formerly known as 141W94 or VX-478) is a second-generation protease inhibitor that is now being made available in the United States to certain patients through an early access program.
GENEVA, June 30 /PRNewswire/ -- Vertex Pharmaceuticals and Glaxo Wellcome's potent new second-generation protease inhibitor, amprenavir (VX-478, 141W94, USAN approved) may have a role in helping the recovery of the immune systems of people with HIV infection.
13 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced for the first time preliminary 12 week data from an ongoing Phase II study of 141W94 (VX-478), an HIV protease inhibitor currently in Phase III clinical trials.
Additional 141W94 data from a number of treatment regimens is expected in the coming months.
Cross-resistance: HIV isolates obtained from 5 patients during nelfinavir therapy showed a 5- to 93-fold decrease in nelfinavir susceptibility in vitro when compared to matched baseline isolates, but did not demonstrate a concordant decrease in susceptibility to indinavir, ritonavir, saquinavir or 141W94, in vitro.
efficacy of 141W94 (VX-478) plus NRTI (nucleoside reverse transcriptase
trials are intended to support filing for market approval of 141W94 in
July 10 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that its partner, Glaxo Wellcome plc (NYSE: GLX), has begun a pivotal Phase III clinical trial to evaluate the safety and efficacy of 141W94 (VX-478) in combination with nucleoside reverse transcriptase inhibitor therapy in HIV-infected children.
Assistant Director, Antiviral Clinical Research at Glaxo Wellcome, "We are well on track to evaluating 141W94 in a broad patient population.
16 /PRNewswire/ -- The investigational HIV protease inhibitor 141W94 (VX-478) appears to have significant antiviral activity while also being well-tolerated, according to preliminary data from a small Phase I/II study presented today.
Robert Schooley at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), evaluated the tolerability, absorption/metabolism, and efficacy of 141W94 (VX-478) at four orally delivered doses over a period of 28 days.